Welcome to Pharmacosmos Nordic

PHOSPHARE-IBD

IRON DEFICIENCY ANAEMIA (IDA) IS THE MOST COMMON EXTRAINTESTINAL COMPLICATION AFFECTING PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD), AND INTRAVENOUS IRON IS A COMMON TREATMENT FOR IDA IN PATIENTS WITH IBD1  

1.Zoller H, Wolf M, Blumenstein I et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut 2022;0:1-10.

This content is only available if your logged in as a healthcare professional.

Subscribe
to our newsletter

If you want to know more about the scientific content coming from Pharmacosmos related to Monofer (high dose IV Iron) I may at any time unsubscribe from receiving this material through the links in the emails.
Please read more in our Privacy Policy about our processing of your personal data

Learn more

If you want to discuss in more detail about the study material, please reach out to our local medical team.

Jan Alexander Ottosen Berg

Medical Science Liaison, Human Iron
Denmark
jab@pharmacosmos.com

Sara Maria Lindqvist

Medical Manager, Human Iron
Sweden & Norway 
sml@pharmacosmos.com

Pharmacosmos

Please identify if you are a:

On clicking, you will leave Pharmacosmos.us and will be redirected to a product website
;